PulseAugur
EN
LIVE 12:18:53

AI drastically cuts drug discovery timelines, especially in China · 2 sources tracked

By PulseAugur Editorial · [2 sources] ·

AI is significantly accelerating drug discovery timelines, particularly in China. Insilico Medicine, for example, has reduced the time to candidate nomination to around 13 months, a substantial improvement over the traditional four-and-a-half years. This acceleration is achieved by integrating generative AI for target identification and molecule design with laboratory research, and is further enhanced by China's efficient research infrastructure and regulatory processes. Pharmaceutical companies operating in China can potentially shave years off development cycles and bring drugs to market faster than in Western markets. AI

IMPACT Accelerates the development of new pharmaceuticals, potentially leading to faster market entry for novel treatments and reduced R&D costs.

RANK_REASON The cluster discusses significant advancements in AI's application to drug discovery, highlighting reduced timelines and cost efficiencies, particularly within the Chinese pharmaceutical landscape.

Read on Artificial Intelligence News →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

AI drastically cuts drug discovery timelines, especially in China · 2 sources tracked

COVERAGE [2]

  1. Mastodon — sigmoid.social TIER_1 English(EN) · [email protected] ·

    📰 Closing the data loop in AI-driven drug discovery Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly

    📰 Closing the data loop in AI-driven drug discovery Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuti... 📰 Source: MIT Technology Re…

    LINKS web.archive.org/…/closing-the-data-loop-i… web.archive.org
  2. Artificial Intelligence News TIER_1 English(EN) · Muhammad Zulhusni ·

    How AI is shortening drug discovery timelines in China

    <p>Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov. The Hong Kong-listed company’s fastest programme reached candi…

RELATED ENTITIES

RELATED TOPICS